Chemaitelly et al.: "COVID-19 primary series and booster vaccination and immune imprinting"; what? 3 dose (includes 1st boost) elevates risk of re-infection vs 2 doses? Original antigenic sin (OAS)?
by Paul Alexander
These results once again raise serious questions as to the repeated injections & boosters for it is clear that antigenic sin operates; immune imprinting, fixation to the initial prime exposure
Yes, OAS in full force! The original prime or exposure prejudices the subsequent immune response to that exposure or similar and potentially life-long.
The potential nightmare is if the virus overcomes the sub-optimal population immune pressure on virus virulence and selects for sub-variants that could cause severe illness in the lower distal lung. Increased infectiousness in the upper respiratory tract is one huge challenge yet it is severe illness in the lower respiratory tract that keeps us up at night and it can happen with this sub-optimal non-sterilizing non-neutralizing vaccine and induced vaccinal antibodies that puts selection pressure on the spike and binding sites (infection and virulence) yet does not eliminate the virus.
This statement by the authors makes no sense when you consider the results, and typical woke writing, politicized garbage:
“These findings do not undermine the short-term public health utility of booster vaccination.”
Bottom line is that the 3rd dose enhanced infection (re-infection) in the vaccinee to omicron (and it’s subvariants) and this is exacerbated with each additional dose. It is classic OAS yet one can argue it is beyond OAS (immune imprinting and thus biased and prejudiced immune response/recall antibodies). Why? What we are finding is that the vaccine is actually causing the virus to become highly infectious as if gaining a property it did not have. The vaccinated are and became infected/re-infected especially in high vaccine coverage nations. With that is the increased risk of illness, severe outcome and death. We have seen this.
This study was an observational, matched, retrospective, cohort design and conducted to investigate differences in incidence of SARS-CoV-2 reinfection in the national cohort of persons who had a primary omicron infection, but different vaccination histories. History of primary-series (two-dose) vaccination was compared to that of no vaccination, history of booster (three-dose) vaccination was compared to that of two-dose vaccination, and history of booster vaccination was compared to that of no vaccination.’